Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 245

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis

Open access
Álvarez-Jiménez, Mario, Parker, Alexandra G., Hetrick, Sarah E., McGorry, Patrick D., Gleeson, John F.·2011·Schizophrenia Bulletin
DOI 10.1093/schbul/sbp129
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The majority of first-episode psychosis (FEP) patients reach clinical remission; however, rates of relapse are high. This study sought to undertake a systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the effectiveness of pharmacological and non-pharmacological interventions to prevent relapse in FEP patients. METHODS: Systematic review and meta-analysis of RCTs. RESULTS: Of 66 studies retrieved, 18 were eligible for inclusion. Nine studies investigated psychosocial interventions and 9 pharmacological treatments. The analysis of 3 RCTs of psychosocial interventions comparing specialist FEP programs vs treatment as usual involving 679 patients demonstrated the former to be more effective in preventing relapse (odds ratio [OR]=1.80, 95% confidence interval [CI]=1.31-2.48; P<.001; number needed to treat [NNT]=10). While the analysis of 3 different cognitive-behavioral studies not specifically intended at preventing relapse showed no further benefits compared with specialist FEP programs (OR=1.95, 95% CI=0.76-5.00; P=.17), the combination of specific individual and family intervention targeted at relapse prevention may further improve upon these outcomes (OR=4.88, 95% CI=0.97-24.60; P=.06). Only 3 small studies compared first-generation antipsychotics (FGAs) with placebo with no significant differences regarding relapse prevention although all individual estimates favored FGAs (OR=2.82, 95% CI=0.54-14.75; P=.22). Exploratory analysis involving 1055 FEP patients revealed that relapse rates were significantly lower with second-generation antipsychotics (SGAs) compared with FGAs (OR=1.47, 95% CI=1.07-2.01; P<.02; NNT=10). CONCLUSIONS: Specialist FEP programs are effective in preventing relapse. Cognitive-based individual and family interventions may need to specifically target relapse to obtain relapse prevention benefits that extend beyond those provided by specialist FEP programs. Overall, the available data suggest that FGAs and SGAs have the potential to reduce relapse rates. Future trials should examine the effectiveness of placebo vs antipsychotics in combination with intensive psychosocial interventions in preventing relapse in the early course of psychosis. Further studies should identify those patients who may not need antipsychotic medication to be able to recover from psychosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/schbul/sbp129

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 63

  1. Sanger, 1999, Olanzapine versus haloperidol treatment in first-episode psychosis, Am J Psychiatry, 156, 79, 10.1176/ajp.156.1.79 · DOI · Paper page
  2. Lieberman, 2003, Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol, Am J Psychiatry, 160, 1396, 10.1176/appi.ajp.160.8.1396 · DOI · Paper page
  3. Schooler, 2005, Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial, Am J Psychiatry, 162, 947, 10.1176/appi.ajp.162.5.947 · DOI · Paper page
  4. Robinson, 1999, Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder, Arch Gen Psychiatry, 56, 241, 10.1001/archpsyc.56.3.241 · DOI · Paper page
  5. Robinson, 2005, Pharmacological treatments for first-episode schizophrenia, Schizophr Bull, 31, 705, 10.1093/schbul/sbi032 · DOI
  6. Rummel, 2003, New generation antipsychotics for first episode schizophrenia, Cochrane Database Syst Rev
  7. Gitlin, 2001, Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia, Am J Psychiatry, 158, 1835, 10.1176/appi.ajp.158.11.1835 · DOI · Paper page
  8. Stephenson, 2000, Delay in treating schizophrenia may narrow therapeutic window of opportunity, JAMA, 283, 2091, 10.1001/jama.283.16.2091 · DOI
  9. Ho, 2003, Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia, Arch Gen Psychiatry, 60, 585, 10.1001/archpsyc.60.6.585 · DOI · Paper page
  10. Penn, 2005, Psychosocial treatment for first-episode psychosis: a research update, Am J Psychiatry, 162, 2220, 10.1176/appi.ajp.162.12.2220 · DOI · Paper page
  11. Almond, 2004, Relapse in schizophrenia: costs, clinical outcomes and quality of life, Br J Psychiatry, 184, 346, 10.1192/bjp.184.4.346 · DOI · Paper page
  12. Weiden, 1995, Cost of relapse in schizophrenia, Schizophr Bull, 21, 419, 10.1093/schbul/21.3.419 · DOI · Paper page
  13. Lehman, 2004, Practice guideline for the treatment of patients with schizophrenia, second edition, Am J Psychiatry, 161, 1
  14. National Institute for Clinical Excellence, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care
  15. Leucht, 2003, Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials, Am J Psychiatry, 160, 1209, 10.1176/appi.ajp.160.7.1209 · DOI · Paper page
  16. Bola, 2003, Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project, J Nerv Ment Dis, 191, 219, 10.1097/01.NMD.0000061148.84257.F9 · DOI
  17. Lenior, 2001, Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention, Br J Psychiatry, 179, 53, 10.1192/bjp.179.1.53 · DOI
  18. Higgins, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]: The Cochrane Collaboration
  19. Review Manager (RevMan) [computer program], Version 5.0.
  20. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  21. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  22. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, Br Med J, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  23. Light, 1984, Organizing a Reviewing Strategy. Summing Up: The Science of Reviewing Research, 13, 10.4159/9780674040243 · DOI · Paper page
  24. Jackson, 2005, A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data, Psychol Med, 35, 1295, 10.1017/S0033291705004927 · DOI
  25. Emsley, 2008, Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study, J Clin Psychopharmacol, 28, 210, 10.1097/JCP.0b013e318167269d · DOI
  26. Haddock, 1999, A pilot study evaluating the effectiveness of individual inpatient cognitive-behavioural therapy in early psychosis, Soc Psychiatry Psychiatr Epidemiol, 34, 254, 10.1007/s001270050141 · DOI · Paper page
  27. Kuipers, 2004, An RCT of early intervention in psychosis: Croydon Outreach and Assertive Support Team (COAST), Soc Psychiatry Psychiatr Epidemiol, 39, 358, 10.1007/s00127-004-0754-4 · DOI
  28. Linszen, 1996, Treatment, expressed emotion and relapse in recent onset schizophrenic disorders, Psychol Med, 26, 333, 10.1017/S0033291700034723 · DOI · Paper page
  29. Robinson, 2006, Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes, Am J Psychiatry, 163, 2096, 10.1176/ajp.2006.163.12.2096 · DOI
  30. Gitlin, 2001, Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia, Am J Psychiatry, 158, 1835, 10.1176/appi.ajp.158.11.1835 · DOI · Paper page
  31. Berger, 2008, Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years, J Clin Psychiatry, 69, 1702, 10.4088/JCP.v69n1105 · DOI
  32. Sikich, 2008, Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study, Am J Psychiatry, 165, 1420, 10.1176/appi.ajp.2008.08050756 · DOI · Paper page
  33. Craig, 2004, The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis, Br Med J, 329, 1067, 10.1136/bmj.38246.594873.7C · DOI · Paper page
  34. Grawe, 2006, Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study, Acta Psychiatr Scand, 114, 328, 10.1111/j.1600-0447.2006.00799.x · DOI
  35. Petersen, 2005, A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness, BMJ, 331, 602, 10.1136/bmj.38565.415000.E01 · DOI · Paper page
  36. Jackson, 2008, Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus befriending for first-episode psychosis: the ACE project, Psychol Med, 38, 725, 10.1017/S0033291707002061 · DOI
  37. Tarrier, 2004, Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial, Br J Psychiatry, 184, 231, 10.1192/bjp.184.3.231 · DOI · Paper page
  38. Edwards, 2006, Randomised controlled trial of a cannabis-focused intervention for young people with first-episode psychosis, Acta Psychiatrica Scandinavica, 114, 109, 10.1111/j.1600-0447.2006.00783.x · DOI
  39. Gleeson, 2009, A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients, J Clin Psychiatry, 70, 477, 10.4088/JCP.08m04407 · DOI
  40. Leavey, 2004, A randomized controlled trial of a brief intervention for families of patients with a first episode of psychosis, Psychol Med, 34, 423, 10.1017/S0033291703001594 · DOI
  41. Zhang, 1994, Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou, Jiangsu, Br J Psychiatry Suppl, 24, 96, 10.1192/S0007125000293045 · DOI
  42. Crow, 1986, A randomised controlled trial of prophylactic neuroleptic treatment, Br J Psychiatry, 148, 120, 10.1192/bjp.148.2.120 · DOI · Paper page
  43. Kane, 1982, Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia, Arch Gen Psychiatry, 39, 70, 10.1001/archpsyc.1982.04290010048009 · DOI · Paper page
  44. McCreadie, 1989, The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group, Acta Psychiatr Scand, 80, 597, 10.1111/j.1600-0447.1989.tb03032.x · DOI
  45. Gaebel, 2007, Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia, J Clin Psychiatry, 68, 1763, 10.4088/JCP.v68n1116 · DOI
  46. Lieberman, 2003, Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine, Neuropsychopharmacology, 28, 995, 10.1038/sj.npp.1300157 · DOI · Paper page
  47. Kahn, 2008, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial [see comment], Lancet, 371, 1085, 10.1016/S0140-6736(08)60486-9 · DOI · Paper page
  48. 1988, The Scottish First Episode Schizophrenia Study V. One-year follow-up. The Scottish Schizophrenia Research Group, Br J Psychiatry, 152, 470, 10.1192/bjp.152.4.470 · DOI
  49. Birchwood, 1998, Early intervention in psychosis. The critical period hypothesis, Br J Psychiatry Suppl, 172, 53, 10.1192/S0007125000297663 · DOI · Paper page
  50. McGorry, 1996, EPPIC: an evolving system of early detection and optimal management, Schizophr Bull, 22, 305, 10.1093/schbul/22.2.305 · DOI · Paper page
  51. Carbone, 1999, Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach, Acta Psychiatr Scand, 100, 96, 10.1111/j.1600-0447.1999.tb10830.x · DOI
  52. Larsen, 2001, Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment, Am J Psychiatry, 158, 1917, 10.1176/appi.ajp.158.11.1917 · DOI · Paper page
  53. Cullberg, 2002, One-year outcome in first episode psychosis patients in the Swedish Parachute project, Acta Psychiatr Scand, 106, 276, 10.1034/j.1600-0447.2002.02376.x · DOI
  54. Harris, 2005, The relationship between duration of untreated psychosis and outcome: an eight-year prospective study, Schizophr Res, 79, 85, 10.1016/j.schres.2005.05.024 · DOI · Paper page
  55. Bertelsen, 2008, Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial, Arch Gen Psychiatry, 65, 762, 10.1001/archpsyc.65.7.762 · DOI · Paper page
  56. Edwards, 2005, Developing services for first-episode psychosis and the critical period, Br J Psychiatry Suppl, 48, s91, 10.1192/bjp.187.48.s91 · DOI
  57. Pitschel-Walz, 2001, The effect of family interventions on relapse and rehospitalization in schizophrenia–a meta-analysis, Schizophr Bull, 27, 73, 10.1093/oxfordjournals.schbul.a006861 · DOI · Paper page
  58. Alvarez-Jimenez, Differential predictors of critical comments and emotional over-involvement in first-episode psychosis [published online ahead of print December 15, 2008], Psychol Med
  59. Bola, 2002, At issue: predicting drug-free treatment response in acute psychosis from the Soteria project, Schizophr Bull, 28, 559, 10.1093/oxfordjournals.schbul.a006964 · DOI
  60. Lehtinen, 2000, Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?, Eur Psychiatry, 15, 312, 10.1016/S0924-9338(00)00400-4 · DOI
  61. Ciompi, 1992, The pilot project ‘Soteria Berne'. Clinical experiences and results, Br J Psychiatry Suppl, 161, 145, 10.1192/S0007125000297183 · DOI
  62. Wirshing, 2004, Schizophrenia and obesity: impact of antipsychotic medications, J Clin Psychiatry, 65, 13
  63. Lasser, 2007, Remission in schizophrenia: applying recent consensus criteria to refine the concept, Schizophr Res, 96, 223, 10.1016/j.schres.2007.05.003 · DOI

Cited by

See all 245

Metadata

Authors
Álvarez-Jiménez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. F.
Venue
Schizophrenia Bulletin
Publisher
Oxford University Press (OUP)
Published
2009-11-09
Volume
37
Issue
3
Pages
619-630
ISSN
  • 0586-7614 (ISSN-L)
  • 1745-1701
DOI
10.1093/schbul/sbp129
OpenAlex
W2154443881
Cited by
245
References
12
FWCI
1.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis. https://app.cochat.ai/papers/10.1093/schbul/sbp129
The paper
Álvarez-Jiménez, M., Parker, A. G., Hetrick, S. E., McGorry, P. D., & Gleeson, J. F. (2011). Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbp129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.